Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"DR FALK PHARMA NEW ZEALAND LIMITED, Clinician, Consumer",Budesonide orodispersible tablets,"Eosinophilic oesophagitis, 2nd line after fluticasone",Budesonide orodispersible tablets,Options for investment,,Alimentary Tract and Metabolism
